Suzetrigine (formerly VX-548) is an investigational oral, selective NaV1.8 pain signal inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. Na...
- VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - BOSTON--(BUSINESS WIRE)--Ju...
Neither trial met this key secondary endpoint (abdominoplasty: LS mean difference between VX-548 and HB/APAP = 6.6 (95% CI: -5.4, 18.7; P=0.2781); bunionectomy: LS mean difference between VX-548 and HB/APAP = -20.2 (95% CI: -32.7, -7.7; P=0.0016)). The second key secondary ...
- VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - ...
–Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and bunionectomy randomized controlled trials –– Treatment
And then any update on where we might see the full phase 3 data for VX-548 this fall? Thank you. Reshma Kewalramani--President and Chief Executive Officer Hey, Terence, let me take the second question first. I think it's now been released. The VX-548 suzetrigine data have been accep...
What's the internal bar for actually moving VX-548 into a registrational program? Do you need to see a certain delta versus what the placebo arm shows at 12 weeks? Or would a faster separation in the initial first few weeks on treatment versus placebo actually be enough of a signal to ...
“Our R&D strategy contemplates the high-risk nature of drug development and therefore includes a portfolio approach to each of our disease areas of interest. In AATD, while disappointed by the VX-814 outcome, we look forward to the VX-864 Phase 2 proof-of-concept data in the first half ...
Vertex Provides Update to Ongoing Phase 2 Study Evaluating Combinations of Telaprevir and VX-222 for the Treatment of HepaCAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a modification of its Phase 2 clinical trial evaluating 12-week, ...
Toggle SummaryApr 18, 2024Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain View HTML PDF Version Toggle SummaryApr 10, 2024Vertex Enters Into Agreement to Acquire Alpine Immune Sciences View HTML PDF Version ...